Vimarsana
Biggest News Aggregation in the World

Nasdaq Blue News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Blue. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Blue Today - Breaking & Trending Today

BLUE LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, - Vimarsana News

BLUE LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL,

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities...

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio - Vimarsana News

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities...

bluebird bio (NASDAQ:BLUE) Trading Up 4.2% - Vimarsana News

bluebird bio (NASDAQ:BLUE) Trading Up 4.2%

Bluebird bio, Inc. (NASDAQ:BLUE – Get Free Report)’s share price was up 4.2% during mid-day trading on Wednesday . The company traded as high as $1.27 and last traded at $1.25. Approximately 2,527,252 shares were traded during trading, a decline of 74% from the average daily volume of 9,864,597 shares. The stock had previously closed […]

Source: wkrb13.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio - Vimarsana News

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio

NEW YORK, March 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities...

bluebird bio, Inc. (NASDAQ:BLUE) Forecasted to Post Q1 2024 Earnings of ($0.29) Per Share - Vimarsana News

bluebird bio, Inc. (NASDAQ:BLUE) Forecasted to Post Q1 2024 Earnings of ($0.29) Per Share

Bluebird bio, Inc. (NASDAQ:BLUE – Free Report) – Analysts at Leerink Partnrs dropped their Q1 2024 earnings estimates for bluebird bio in a report issued on Tuesday, March 26th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will earn ($0.29) per share for the quarter, down from their prior forecast of ($0.24). […]